SMA Newsroom

Oct 2, 2023

Community Update from Biohaven

We are pleased to share with you the latest press release issued by Biohaven. The biopharmaceutical company completes enrolment in Pivotal Phase 3 study of taldefgrobep alfa in spinal muscular atrophy.



RESILIENT is a Phase 3 placebo-controlled, double-blind trial designed to evaluate the efficacy and safety of taldefgrobep at 48 weeks as an adjunctive therapy for participants who are already taking a stable dose of nusinersen, risdiplam and/or have a history of treatment with onasemnogene abeparvovec-xioi, compared to placebo. The study is not restricted nor limited to patients based on ambulatory status or classification of SMA.